Citius Pharmaceuticals reports fiscal Q3 2026 results as LYMPHIR launch continues
The company reported $7.1 million in nine-month LYMPHIR revenue and $17 million in cash, while citing early-stage data expanding the drug's potential use beyond cutaneous T-cell lymphoma.
Citius Pharmaceuticals reported financial results for the fiscal third quarter ended June 30, 2026, in a press release dated August 14, 2026, alongside a business update covering its majority-owned subsidiary, Citius Oncology, Inc.
On the commercial side, the company said institutional vial orders grew as new institutions placed orders, and LYMPHIR reached 44 sites including leading academic oncology centers, NCCN institutions and community infusion centers.1 Institutional demand accelerated further after quarter end, with 383 vials ordered by institutions from wholesalers in July, described as the largest vial order month to date, and near universal payer coverage with no reimbursement denials or preauthorization barriers reported.1 The company also said it added 21 commercial field-based professionals and eight medical science liaisons to Citius Oncology's team, completing nationwide deployment in August 2026 through EVERSANA, described as the company's exclusive commercialization partner.1
On the pipeline, investigator-initiated Phase 1 data were presented in 2026 at two meetings. At ASCO, LYMPHIR combined with pembrolizumab in recurrent or refractory gynecologic malignancies produced a 24% overall response rate and 48% clinical benefit rate, with median progression-free survival of 20.5 months among patients achieving clinical benefit.1 At the ASTCT and CIBMTR Tandem Meetings, LYMPHIR given ahead of CAR-T therapy in high-risk relapsed or refractory DLBCL showed an 86% overall response rate, including 57% complete response and 29% partial response, with the drug described as well tolerated and no dose-limiting toxicities observed.1
On financing, the company reported $17.0 million in cash and cash equivalents as of June 30, 20261, after closing a registered direct offering in April 2026 for approximately $4.5 million in net proceeds, receiving about $9.7 million from warrant exercises, and funding $10.0 million under the first tranche of a Citius Oncology senior secured term loan facility of up to $25.0 million.1 Revenue for the nine months ended June 30, 2026 totaled $7.1 million, compared with no revenue in the same period a year earlier.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.